Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 64 results for "Byetta"

Human medicines European public assessment report (EPAR): By...

This is a summary of the European public assessment report (EPAR) for Byetta. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ... European Medicines Agency, 1 week ago

An Exemplary "Learned Intermediary" Win for Lilly and Byetta

A tip of the hat to our friend and former colleague Ken Zucker from Pepper Hamilton , who achieved this victory and sent us the decision. In the consolidated California Byetta litigation, 2015WL 663211 (Cal. Super. Feb. 26, 2015), defendant Eli ...
 JD Supra2 months ago

Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

The global peptide therapeutics market report provides detailed analysis, market size, and forecast for therapeutic peptides approved for various indications. The market is studied from four major perspectives: applications, route of administration, ...
 Global Information Inc5 days ago Peptide Therapeutics Market Expected to Reach USD 23.7 Billion Globally in 2020  QMED2 weeks ago

ELITE Strategist Jay Carter of AbelsonTaylor

Feature Articles by on May 19th, 2015 0 Flares 0 Flares × Jay Carter SVP, Director of Strategy Services The Forward Thinker Prevacid, Neulasta, Aranesp, Actos, Byetta, Rituxan and Herceptin. All of those brands have two things in common.
 PM 3605 days ago

Flamel's (FLML) CEO Mike Anderson on Q1 2015 Results - Earnings Call Transcript

Operator Please standby, we are about to begin. Good morning, ladies and gentlemen. And welcome to the Flamel Technologies First Quarter 2015 Earnings Call. Please note that this call is being recorded. I would now like to turn the call over ...
 Seeking Alpha1 week ago Corium International's (CORI) CEO Peter Staple on Q2 2015 Results - Earnings Call Transcript  Seeking Alpha1 week ago

FirstView Barriers - An Analysis of Market Barriers in Type 2 Diabetes (EU5)

What market barriers are influencing the Type 2 Diabetes (T2DM) market? From price to availability to reimbursement factors, provides insights that can help develop, shape and refine your brand strategies. Also Available is FirstView Barriers - An ...
 Global Information Inc1 week ago

Take Charge of Diabetic Care

The Centers for Disease Control (CDC) now estimates 40% of all American adults will be affected by diabetes.1 Of adults with the disease, 28.5% are now diagnosed with DR or diabetic macular edema (DME), or both.2 That's more than eight million ...
 Review of Optometry1 week ago Should The FDA Require CV Outcome Studies For Diabetes Drugs Before Approval?  Forbes.com1 month ago
Lawyers & Settlements

Possible Lawsuit: Victoza Side Effects - Pancreatic and Thyroid Cancer

In March 2013 the US Food and Drug Administration (FDA) announced results of a study suggesting Victoza side effects could include an increased risk of Victoza pancreatitis. Victoza has already reportedly been linked in animal studies to an ...
 Lawyers & Settlements2 weeks ago

Profil Institute for Clinical Research, Inc. Expands Clinical Development Leadership Team With Prominent Industry Experts And

/PRNewswire/ --Profil Institute for Clinical Research, Inc., an early engagement clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced todaythe appointment of Dr. Michael Trautmann as Senior Director of Drug ...
 BioSpace2 weeks ago Profil Institute Expands Clinical Development Leadership Team With Prominent Industry Experts Drs. Michael Trautmann and Gordon Brandt  Fat Pitch Financials2 weeks ago
[x]  
Lawyers & Settlements

Possible Lawsuit: Januvia

Januvia is a drug prescribed to help treat adults with type-2 diabetes. In September 25, 2009 the FDA issued a revision to the warning label of the drug Januvia or Janumet--a combination drug comprised of Januvia and Metformin--regarding Januvia ...
 Lawyers & Settlements2 weeks ago Do Januvia Side Effects Include Cancer of the Pa…  Peoples Pharmacy2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less